Karyopharm Therapeutics reported $-34409000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Abbott ABT:US $ 3735M 316M
Abbvie ABBV:US $ 7127M 482M
Amgen AMGN:US $ 3341M 185M
Astrazeneca AZN:US $ 4187M 687M
AstraZeneca AZN:LN 4187M 687M
Avrobio Inc AVRO:US $ -29019000 1.49M
Biocryst Pharmaceuticals BCRX:US $ -49.64M 2.37M
Bristol Myers Squibb BMY:US $ 5772M 404M
Enanta Pharmaceuticals ENTA:US $ -33.02M 3.4M
Epizyme EPZM:US $ -49.63M 0.33M
Karyopharm Therapeutics KPTI:US $ -34409000 81.51M
Merk MRK:US $ 6179M 492M
Mirati Therapeutics MRTX:US $ -183.59M 12.92M
Nektar Therapeutics NKTR:US $ -109.47M 0.5M
Novartis NOVN:VX SF 4552M 346M
Novartis NVS:US $ 4552M 346M
Sangamo Biosciences SGMO:US $ -42.43M 5.29M
Takeda 4502:JP Y 150655M 139878M
Tg Therapeutics TGTX:US $ -66.8M 26.07M
Ultragenyx Pharmaceutical RARE:US $ -132.54M 33.51M